ASBMB calls for 10% budget increase for NIGMS

In testimony to federal appropriators, the society argues a big boost for the institute is long overdue
Marissa Locke Rottinghaus
March 31, 2023

The American Society for Biochemistry and Molecular Biology submitted testimony to the U.S. House Appropriations Committee on March 22 outlining its recommended budgets for major scientific funding agencies. Notably, the society requested a significant 10% increase in the budget for the National Institute of General Medical Sciences, which is part of the National Institutes of Health. 

“The ASBMB has a longstanding history of advocating for NIGMS and its researchers, and the majority of our members are funded by and rely on NIGMS to advance their research,” Sarina Neote, public affairs director of the ASBMB, said. “The rising cost of science has made research difficult for our members and all scientists. Therefore, appropriators must not only adjust the NIH budgets to keep up with inflation but also invest in the scientists leading the way in areas like biotechnology, biophysics and molecular biology who have a home in NIGMS and NIGMS-funded labs.” 

According to the ASBMB testimony, “The NIGMS is the largest funder of fundamental biomedical research, as well as biomedical research training programs to support the bioeconomy and its workforce.” In fact, NIGMS awards more than 11% of NIH research grants. However, NIGMS has been historically underfunded, and its budget usually represents only 6% of the total NIH budget. Over the past decade, the NIGMS budget has increased only 21%, whereas other institutes such as the National Institute of Allergy and Infectious Diseases have received more than a 40% increase. A 10% boost for NIGMS, Neote, said is modest in comparison. 

The NIGMS is an established leader in funding excellent, innovative scientific researchers and has supported 60% of NIH-funded Nobel laureates. In addition, the NIGMS is a leading institute funding biotechnology and bioengineering research, which is one of President Joe Biden’s priorities as evidenced by his recent executive order “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe and Secure American Bioeconomy.”  

In addition, the NIGMS awards the most (more than 25%) NIH diversity supplements across the 32 centers and institutes at the NIH. Going by NIH’s recent requests for information, the funder intends to make diversity, equity, accessibility and inclusion a priority, and NIGMS is leading the way.  

The ASBMB also recently released a statement on Biden’s budget request. In it, the society expressed support for Biden’s proposed increases for the National Science Foundation and Department of Energy budgets. However, the society strongly opposed Biden’s NIH funding request, which proposed a minute increase of 1.7% for all NIH funding, specifically citing its negative impact on NIGMS. 

The society recommended:

  • $3.52 billion for the NIH NIGMS

  • $8.9 billion for the Office of Science at the DOE

  • $12 billion for the NSF 

In light of the rising cost of scientific research, the society called Biden’s NIH budget request “disappointing,” adding that “under Biden’s budget, the NIGMS would have to reduce funding for research project grants to offset inflation. This means scientists will have to abandon their projects. The U.S. research enterprise needs reliable, sustained investments in scientific funding, and Biden’s proposed budget for NIH falls short.” 

ASBMB's other appropriations asks this year are an increase in the DOE Office of Science budget to support research in clean energy, climate change, emerging technologies and more. The society’s recommendation is similar to Biden’s proposed 13.6% increase, which will fund biological and environmental research. 

In addition, the ASBMB showed support for continued funding for NSF that specifically bolsters the CHIPS and Science Act, which it said will “re-energize scientific research and training supported by the NSF” and “ensure the U.S. remains a global leader in innovation.” Its recommendation aligned with the 18.61% increase in Biden’s proposed budget.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Marissa Locke Rottinghaus

Marissa Locke Rottinghaus is the science and policy communications specialist for the ASBMB.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Policy

Policy highlights or most popular articles

'I hope that our actions show our members that we are doing our best to support them'

'I hope that our actions show our members that we are doing our best to support them'

June 6, 2023

A Q&A with ASBMB Policy Manager Raechel McKinley on the organization’s national-level advocacy for LGBTQIA+ scientists, trainees and students.

State laws change the landscape for LGBTQIA+ scientists

State laws change the landscape for LGBTQIA+ scientists

May 31, 2023

New legislation in the past 16 months has banned gender affirming care for transgender teens, teaching children about sexual orientation and gender identity, and drag shows.

Meet the 2023 ASBMB Advocacy Training Program delegates

Meet the 2023 ASBMB Advocacy Training Program delegates

May 24, 2023

ASBMB announces a new cohort of 12 ASBMB Advocacy Training Program delegates who will learn about science policy and advocacy through this summer externship

ASBMB members meet with lawmakers on the Hill

ASBMB members meet with lawmakers on the Hill

May 18, 2023

In 48 meetings, scientists advocated for budget increases for NIH, NSF and DOE.

Researchers to advocate for fundamental science on Capitol Hill
News from the Hill

Researchers to advocate for fundamental science on Capitol Hill

May 17, 2023

Sixteen ASBMB researchers from 16 states to meet with U.S. senators and representatives on Capitol Hill to advocate for basic science research funding for NIH, NSF, DOE

Will new FDA rules help dial back expedited drugs?

Will new FDA rules help dial back expedited drugs?

May 6, 2023

Recent reforms could require companies to perform follow-up studies on drugs that received accelerated approval.